Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Acute Bronchiolitis
Interventions
DRUG

3% Hypertonic Saline

Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.

DRUG

0.9 % normal saline

Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.

Trial Locations (1)

75235

UT Southwestern Medical Center; Children's Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02029040 - Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis | Biotech Hunter | Biotech Hunter